The African Center for Research on End-of-Life Care (ACREOL) comprises multicultural and multidisciplinary African research projects collaborating with ACREOL’s international partners. The center aspires to leverage existing practices on End-of-life care through its work with African networks in palliative care and end-of-life care. Our evidence-based research, filtered through the lens of African perspectives, aims to influence and support policymakers and stakeholders.

Research Areas

1. End-of-life care research
2. Impact evaluation research
3. Feasibility studies
4. Surveys
5. Anthropology & social science studies
6. Medical Research
7. Operational and action research
8. Clinical trials
9. Genomic and Epigenetic studies
10. Antimicrobial resistance and metagenomic

Other services:

1. Fund management for research projects
2. Coordination of research projects
3. Capacity building on palliative care
4. Capacity building of research methodology and biostatistics

Our Core Values

1. Accountability and responsibility
2. Innovation and creativity
3. Customer satisfaction
4. Teamwork and collaboration
5. Respect and diversity
6. Continuous improvement
7. Sustainability and social responsibility
8. Results-oriented
9. Adaptability and flexibility

Past projects and ongoing:

1. . PATH
   In collaboration with ACREOL, PATH planned to undertake a study in Rwanda to estimate the ongoing costs of delivering HPV vaccines and understand the contextual factors of the delivery approach for the HPV vaccination program. PATH will lead the data collection activities in collaboration and coordination with the Rwandan expanded program on immunization (EPI).
2. . CDC Foundation
   The Bloomberg Philanthropies Data for Health Initiative, in collaboration with ACREOL, is providing technical assistance in low- and middle-income countries worldwide to improve the collection and use of public health data. The U.S. Centers for Disease Control and Prevention (CDC), the CDC Foundation, and Vital Strategies (VS) are the leaders of the Initiative’s Data Impact component, which supports ministries of health in using data to improve policymaking and decision-making. The Data Impact Program (DIP) empowers governments to use data strategically to establish priorities, target resources, develop legal and regulatory initiatives, and plan programs to improve the health of their citizens. The DIP also works with ministries to establish or strengthen existing public health bulletins (PHBs).
3. . HuroneAI
   HuroneAI, in collaboration with ACREOL, is conducting a study to determine if the model is ready for widespread clinical use by monitoring and learning from its usage on the field and addressing challenges centered on treatment compliance, side effects management, access to second opinion reviews and implementing a platform for patient-reported outcomes. Ultimately, we want to show that the app can save oncologists time, reduce treatment misinformation, reduce the cost of consultation and travel for patients, increase the efficiency and quality of oncologists, and improve treatment compliance.
4. Armaceutica
   Title: A Phase 2a, multi-center, randomized, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of pyronaridine as an Add-on therapy in adults with acute lymphoblastic leukemia and Acute Myeloid Leukemia.
   A Phase 2a clinical trial on up to n=200 male and female subjects aged 18 and over who were diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Subjects are randomized in approximately a 1:1 ratio to receive standard-of-care treatment plus either pyronaridine or placebo. Quality-of-life parameters are measured. Visits include physical examinations and blood draws for CBC and CMP.
5. ELEKTA Foundation
   With support from the Rwanda Biomedical Center and the Elekta Foundation, ACREOL will create a model palliative care network in the Gicumbi district in Rwanda. We have aimed to create district palliative care networks that are integrated into the government healthcare system, affordable, and thus both sustainable and scalable, and that measurably improve the quality of life of advanced cervical cancer.
6. ABBOTT: In Country Evaluation” for clinical performance of the Determine™ TB LAM Ag Rapid in a non-laboratory setting                                                                                                                                                                          The study will be conducted to evaluate the diagnostic accuracy (sensitivity and specificity) of the DetermineTM TB LAM Ag test for the rapid, qualitative detection of Mtb using urine samples.
   When a TB test is ordered for the standard of care of patients meeting the inclusion criteria and none of the exclusion criteria, the patient will be asked if they would consent to participate in the evaluation study.